National Vision: Strategic Mix Shift and Margin Expansion Support Buy Rating Despite Near-Term Traffic Headwinds

William Blair analyst Dylan Carden has maintained their bullish stance on EYE stock, giving a Buy rating on March 2.

Dylan Carden has given his Buy rating due to a combination of factors, starting with National Vision’s ability to deliver comparable-sales growth and a meaningful earnings beat, largely driven by stronger pricing and favorable product mix that expanded margins ahead of expectations. He also notes that management’s 2026 outlook for comps, operating income, and EPS is at or slightly above consensus, reinforcing confidence that current momentum can be sustained.

At the same time, Carden acknowledges softer self-pay traffic and the risk that higher pricing may pressure value-oriented customers, but he views these declines as a manageable by-product of a deliberate shift toward need-based, higher-yield business. Because the company remains underexposed in attractive areas like managed care, progressive lenses, and outside prescriptions—all of which are now key growth drivers—he believes these strategic changes can support more durable traffic and profit growth over time, justifying a Buy recommendation despite near-term volume headwinds.

In another report released on March 2, Barclays also maintained a Buy rating on the stock with a $32.00 price target.